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ABSTRACT
Background and Objectives: In patients with ST-segment elevation myocardial infarction (STEMI) and multivessel dis-
ease, complete revascularization (CR) for non-culprit lesions is not routinely recommended. The aim of this study was to 
compare the clinical outcomes of multivessel compared with infarct-related artery (IRA)-only revascularization in patients 
undergoing primary percutaneous coronary intervention (PCI) for STEMI. Subjects and Methods: From the Korean 
Acute Myocardial Infarction Registry (KAMIR) database, 1,094 STEMI patients with multivessel disease who underwent 
primary PCI with drug-eluting stents were enrolled in this study. The patients were divided into two groups: culprit-vessel-
only revascularization (COR, n=827) group; multivessel revascularization, including non-IRA (MVR, n=267) group. The 
primary endpoint of this study included major adverse cardiac events (MACEs), such as death, myocardial infarction, or tar-
get or nontarget lesion revascularization at one year. Results: There was no difference in clinical characteristics between the 
two groups. During the one-year follow-up, 102 (15.2%) patients in the COR group and 32 (14.2%) in the MVR group ex-
perienced at least one MACE (p=0.330). There were no differences between the two groups in terms of rates of death, myo-
cardial infarction, or revascularization (2.1% vs. 2.0%, 0.7% vs. 0.8%, and 11.7% vs. 10.1%, respectively; p=0.822, 0.910, and 
0.301, respectively). The MACE rate was higher in the incompletely revascularized patients than in the completely revascu-
larized patients (15% vs. 9.5%, p=0.039), and the difference was attributable to a higher rate of nontarget vessel revascular-
ization (8.6% vs. 1.8%, p=0.002). Conclusion: Although multivessel angioplasty during primary PCI for STEMI did not re-
duce the MACE rate compared with culprit-vessel-only PCI, CR was associated with a lower rate of repeat revascularization 
after multivessel PCI. (Korean Circ J 2011;41:718-725)
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Introduction
The incidence of acute myocardial infarction (AMI) in 
South Korea increased 2.6-fold from 1997 to 2007.
1) From the 
Korean Acute Myocardial Infarction Registry (KAMIR) data 
between November 2005 and December 2007, ST-segment 
elevation myocardial infarction (STEMI) accounted for 60% 
of all AMI cases,
2) with 52% of the STEMI patients having sig-
nificant stenosis of the noninfarct-related arteries.
3) The pa-
thophysiological process in AMI is not limited to a single co-
ronary lesion but involves the whole coronary arterial tree.
4) 
These patients with multivessel disease are at a higher risk of 
cardiogenic shock as well as in-hospital and long-term morta-
lity than the cases of single-vessel disease.
5)6) Moreover, pati-
ents with multiple complex lesions have a high incidence of re-
current acute coronary syndrome and revascularization;
4) how-
ever, in multivessel coronary intervention in the context of 
AMI, there are concerns about procedure-related complica-
tions,
7) lower success rates,
8) and increased contrast use and 
nephropathy.
9) Therefore, both the American College of Car-
diology/American Heart Association (ACC/AHA) 2004 gui-
delines and the ACC/AHA/Society for Cardiac Angiography 
and Interventions 2005 guidelines have recommended that 
simultaneous coronary intervention for nonculprit lesions sh-
ould not be performed in hemodynamically stable patients 
because this approach may be associated with an increased 
risk of adverse outcomes.
10)11) Recently, due to advances in de-
vices, antiplatelet therapy, and technology, complete revas-
cularization (CR) can safely be accomplished,
8) and a recent 
randomized trial has shown that in a contemporary homoge-
neous cohort of patients with STEMI and multivessel coronary 
artery disease (CAD) treated with primary percutaneous coro-
nary intervention (PCI), culprit-lesion-only angioplasty was 
associated with the highest rate of cardiac events compared 
with multivessel treatment, with the patients scheduled for st-
aged revascularization experiencing a similar rate of major ad-
verse cardiac events (MACEs) as the patients undergoing com-
plete simultaneous treatment of noninfarct-related artery (IRA).
12) 
Therefore, the optimal management of patients with multi-
vessel disease in this setting remains still unclear.
The aim of this study was to compare the one-year clinical 
outcomes between the two different strategies during prima-
ry PCI with drug-eluting stents (DES) in patients with STEMI 
and multivessel CAD.
Subjects and Methods
Patient population and study design
This study is based on a database collected by KAMIR. KA-
MIR is a prospective, multicenter, observational registry de-
signed to examine current epidemiology, in-hospital manage-
ment, and outcome of patients with AMI in South Korea in 
commemoration of the 50th anniversary of the Korean Cir-
culation Society.
13)14) Fifty hospitals with facilities for prima-
ry PCI participated in this study. Well-trained study coordi-
nators collected data based on the standard protocol, and 
registered onto the web-based program. The ethics commit-
tee of each participating hospital approved the study proto-
col. The purpose and methods used to register patients in 
the KAMIR study have been previously described.
15)
From the KAMIR database (14,885 patients), data of 3,791 
eligible STEMI patients with multivessel CAD (defined as 
>70% diameter stenosis of two or more epicardial coronary ar-
teries or their major branches by visual estimation) and who 
underwent primary PCI using drug-eluting stents within the 
period from November 2005 to November 2008 were collected.
ST-segment elevation myocardial infarction patients with 
prolonged (more than 30 minutes) chest pain starting less 
than 12 hours before hospital arrival, typical electrocardiogra-
phy changes, and a door-to-balloon time of less than 120 min-
utes were included (Fig. 1).
Patients with cardiogenic shock at presentation (systolic blo-
od pressure: ≤90 mm Hg), left main coronary disease (≥50% 
diameter stenosis), and receiving bare-metal stents were ex-
cluded from the study. The eligible patients were divided into 
two groups and were further divided into two subgroups:
1) Culprit-vessel-only revascularization (COR) group: the 
IRA only was dilated, and the other arteries were left untreat-
ed during the primary procedure or index hospitalization.
2) Multivessel revascularization (MVR) group: revascula-
rization of more than one vessel.
3) Complete revascularization subgroup: the IRA was op-
ened, followed by dilatation of all other significantly narrowed 
arteries during the primary procedure or index hospitaliza-
tion.
4) Incomplete revascularization (IR) subgroup: the IRA was 
successfully opened, followed by dilatation of only the signi-
ficantly narrowed artery in three-vessel disease during the pri-
mary procedure or index hospitalization.
Definitions and endpoints
The diagnosis of AMI was based on clinical presentations, 
increased levels of cardiac biomarkers (increase in levels of 
creatine kinase-MB, troponin-I, or troponin-T), and 12-lead 
electrocardiographic findings. Among these patients, patients 
with an ST-segment elevation of at least 1 mm in two or more 
contiguous limb electrocardiographic leads or 2 mm in pre-
cordial leads were defined as STEMI patients.
The primary endpoint of the study was the incidence of 
MACE defined as cardiac or noncardiac death, reinfarction, 
and repeat coronary revascularization (target vessel or nontar-
get vessel PCI) at one year. As the follow-up period was count-
ed from the date of discharge, in-hospital events (death, rein-
farction) were not defined as MACE. For repeat revascula-720   Multivessel Revascularization in ST-Segment Elevation Myocardial Infarction
rization, all PCIs or coronary artery bypass grafts (CABGs) 
occurring after the baseline procedure were included. Recur-
rent myocardial infarction was defined as recurrent symp-
toms with new electrocardiographic changes reflecting MI 
or increased levels of cardiac biomarkers at least twice the 
upper normal limit.
16) Target lesion revascularization (TLR) 
was defined as PCI for restenosis or other complications of 
treated lesion segment from 5 mm proximal to 5 mm distal 
to the stent.
17) Target vessel revascularization (TVR) was de-
fined as repeated PCI for any segment of the entire coronary 
artery proximal and distal to target lesion, except for TLR.
Percutaneous coronary intervention procedures and 
follow-up
All patients had coronary lesions with ≥50% stenosis in ≥2 
coronary arteries. Coronary arterial lesion type was determin-
ed according to the ACC/AHA classification. The diagnosis of 
the culprit vessel was based on coronary angiographic find-
ings, 12-lead electrocardiogram, two-dimensional echocar-
diogram and noninvasive stress test, if possible. All patients re-
ceived loading doses of aspirin 100-300 mg and clopidogrel 
300-600 mg before PCI. A 50-70 U/kg dose of unfractionat-
ed heparin was used before or during PCI to maintain an ac-
tivated clotting time of 250-300 seconds. After PCI, daily main-
tenance doses of aspirin 100 mg and clopidogrel 75 mg were 
prescribed. A glycoprotein IIb/IIIa inhibitor was used in pa-
tients with large thrombotic burden on angiography at the 
operator’s discretion. Clinical follow-up was performed for 12 
months.
Statistical analysis
Continuous variables are presented as mean±SD, and cat-
egorical variables as percentages. Categorical variables were 
compared among groups using the χ2 test, whereas continu-
ous variables were compared with the analysis of variance test. 
Kaplan-Meier curves were used to represent the survival and 
cumulative incidence of events to the follow-up. For the end-
point “death,” the patients were censored at the time of death 
or at the 12-month follow-up if alive. For MACE, the patients 
were censored at the date of first MACE or at the 12-month 
follow-up. All tests were two-sided, and a p of less than 0.05 
was considered statistically significant. All analyses were per-
formed using the Statistical Package for the Social Sciences 
software, version 18.0 for Windows.
Results
Baseline characteristics
One thousand and ninety four patients with STEMI and 
multivessel CAD who met the inclusion criteria were in-
cluded in the follow-up (Fig. 1). The mean age was 63.1±12.7 
years, and 804 (73.5%) were men. The COR group included 
827 (75.6%) patients, and the MVR group 267 (24.4%) pa-
tients. The CR subgroup included 182 (16.6%) patients, and 
the IR subgroup included 912 (83.4%) patients (Fig. 1). Ta-
ble 1 and 2 show the distribution of the baseline characteris-
tics between the two groups. The two groups were similar in 
terms of age, gender, risk factors, enzymatic infarct size, 
Thrombolysis in Myocardial Infarction (TIMI) flow grade, 
Total KAMIR population (n=14,885)
Patients with NSTEMI or unstable angina or other disease 
on the final diagnosis were excluded (n=6,977).
Patients with single-vessel disease or 
left-main-artery disease (n=4,117)
Patients with thrombolysis or facilitated PCI or elective 
PCI or conservative therapy were excluded (n=955).
Patients whose symptom onset to door time was longer 
than 12 hours, or whose door-to-balloon time was longer 
than 120 minutes, were excluded (n=1,434).
Patients who used BMS or experienced CPR, or whose systolic 
BP is lower than 80 mm Hg, were excluded (n=308).
Patients with STEMI (n=7,908)
Patients with STEMI and multivessel disease (n=3,791)
Patients with STEMI and multivessel disease 
in whom primary PCI was performed (n=2,836)
Patients whose symptom onset to door time was shorter 
than 12 hours and whose door-to-balloon time was shorter 
than 120 minutes (n=1,402)
Patients who used DES and did not experience CPR, 
and whose systolic BP ≥80 mm Hg (n=1,094) 
COR group (n=827) vs. MVR group (n=267)
CR subgroup (n=182) vs. IR subgroup (n=912)
Fig. 1. Flowchart of patients who participated in the study. KAMIR: Korean Acute Myocardial Infarction Registry, NSTEMI: non-ST-elevation 
myocardial infarction, STEMI: ST-elevation myocardial infarction, PCI: percutaneous coronary intervention, BMS: bare-metal stent, CPR: car-
diopulmonary resuscitation, BP: blood pressure, DES: drug-eluting stent, COR: culprit-vessel-only revascularization, MVR: multivessel re-
vascularization, CR: complete revascularization, IR: incomplete revascularization.Hyun Su Jo, et al.   721
and creatinine level, whereas there was a difference in the 
mean left ventricular ejection fraction (LVEF) (higher in the 
MVR group). Nitrate therapy was more frequent in the 
MVR group, whereas the two groups had similar propor-
tions of other therapies.
Cardiovascular events
Forty-four (4.0%) patients died during index hospitaliza-
tion, 31 (2.8%) from cardiac causes. Of them, 43 (5.2%) pati-
ents were in the COR group and in the IR subgroup, and 1 
(0.4%) patient was in the MVR group and in the CR subgr-
oup. The in-hospital mortality was higher in the COR group 
than in the MVR group (p<0.001). However, the multivariate 
analysis after adjusting for age, sex, Killip class, post-MI TIMI 
flow, systolic blood pressure, LVEF, existence or nonexist-
ence of complications, and serum creatinine, did not show that 
Table 1. Baseline clinical characteristics
Variables COR group (n=827) MVR group (n=267) p
Age (years) 63±13 62±12 0.152
Men, n (%) 598 (72.3) 206 (77.2) 0.068
Hypertension, n (%) 400 (49.7) 124 (48.9) 0.388
Systolic BP (mm Hg) 128±400 128±260 0.929
Diabetes mellitus, n (%) 218 (26.8) 075 (29.2) 0.250
Hyperlipidemia, n (%) 57 (8.1) 11 (4.5) 0.062
Family history of CAD, n (%) 52 (7.1) 030 (12.1) 0.016
Prior history of CAD, n (%) 086 (10.4) 23 (8.6) 0.481
Killip class 1.4±0.8 1.4±0.8 0.566
Door-to-balloon time (minutes) 73±23 71±21 0.098
CK-MB level (mg/dL) 239.9±492.7 201.8±192.8 0.469
Serum creatinine level (mg/dL) 1.2±1.2 1.1±1.0 0.577
Left ventricular EF (%) 50.1±11.6 53±10.6 0.004
Three-vessel disease, n (%) 330 (39.9) 110 (41.2) 0.380
Medications at discharge
Aspirin 766 (99.0) 261 (99.2) 0.514
Clopidogrel 762 (98.4) 256 (97.3) 0.183
Statin 654 (84.5) 230 (87.5) 0.142
ACEI 529 (68.3) 190 (72.2) 0.134
Nitrate 348 (45.0) 141 (53.6) 0.009
Beta-blocker 585 (75.6) 202 (76.8) 0.378
In-hospital mortality 43 (5.2) 01 (0.4) <0.001
BP: blood pressure, CAD: coronary artery disease, CK-MB: creatine kinase-myocardial band isoenzyme, EF: ejection fraction, ACEI: angio-
tensin-converting enzyme inhibitor, COR: culprit-vessel-only revascularization, MVR: multivessel revascularization
Table 2. Baseline angiographic characteristics
Variables COR group (n=825) MVR group (n=267) p
Culprit artery
    LAD, n (%) 375 (45.5) 119 (44.6) 0.832
    RCA, n (%) 367 (44.5) 106 (39.7) 0.178
    LCX, n (%)    83 (10.1) 042 (15.7) 0.015
Type B2/C lesion, n (%)* 649 (84.9) 211 (81.8) 0.237
Preprocedural TIMI flow 0.8±1.1 0.9±1.2 0.131
Postprocedural TIMI flow 2.9±0.4 3.0±0.3 0.005
Stent size for target lesion (mm) 26.0±6.40 26.0±6.70 0.937
Total number of stents  1.3±0.6 2.4±1.0 0.001
*Based on the American College of Cardiology/American Heart Association coronary artery lesion definition. LAD: left anterior descending 
artery, RCA: right coronary artery, LCX: left circumflex artery, TIMI: Thrombolysis in Myocardial Infarction, COR: culprit-vessel-only revas-
cularization, MVR: multivessel revascularization722   Multivessel Revascularization in ST-Segment Elevation Myocardial Infarction
the culprit-only PCI was significantly associated with higher 
in-hospital mortality (p=0.995) which had a significant p in 
the univariate analysis. Low post-TIMI flow (odds ratio: 
0.191; 95% confidence interval: 0.044-0.834; p=0.028) and 
the existence of complications during index hospitalization 
(odds ratio: 21.916; 95% confidence interval: 1.145-419.361; 
p=0.028) were significantly associated with higher in-hospi-
tal mortality. The in-hospital mortality was also higher in 
the IR subgroup than in the CR subgroup (p=0.002).
The rates of complications during the procedure were simi-
lar between the two groups. All four acute CVA patients were 
in the COR group. One patient with acute thrombosis was 
in the MVR group and in the CR subgroup. Of the three rein-
farction patients, two were in the COR group, and one was in 
the MVR group and in the CR subgroup. One case of acute 
renal failure was in the MVR group and in the IR subgroup. 
The other complications were ventricular tachycardia, ventri-
cular fibrillation, atrial fibrillation, cardiogenic shock, multi-
organ failure, bleeding, and atrioventricular block.
After a mean follow-up of 9.0±4.2 months from the date 
of discharge, 23 (2.4%) patients died, 14 (1.5%) from cardiac 
causes. Throughout the follow-up, 134 (14.4%) patients ex-
perienced at least one MACE, 102 (14.9%) in the COR group 
and 32 (13.0%) in the MVR group (p=0.379). Seven patients 
(five in the COR group and two in the MVR group) experi-
enced reinfarction (MI) while 107 patients (82 in the COR 
group and 25 in the MVR group) underwent re-PCI or CA-
BG (Table 3). The Kaplan-Meier analysis showed no signifi-
cant difference between the two groups for survival free of 
total MACE and of all kinds of MACE (Fig. 2).
However, the Kaplan-Meier analysis showed significant 
differences between the two subgroups (the CR and IR sub-
groups) for survival free of total MACE and nontarget vessel 
PCI (Table 4). The survival free of total MACE and nontar-
get vessel PCI was lower in the IR subgroup (p=0.039 and 
0.002, respectively) (Fig. 3). Fifteen of 85 patients in the MVR 
group and in the IR subgroup experienced at least one MACE. 
Of them, nine patients underwent nontarget vessel PCI.
Discussion
This study was designed to compare MVR with COR in 
patients with STEMI and multivessel CAD; it is the first study 
to compare MVR with COR in patients with STEMI in Asia. 
The main finding of the present study was that in hemodyna-
mically stable patients with multiple coronary lesions treated 
by primary PCI using DES, MVR had a lower rate of in-hos-
pital mortality and, after a mean follow-up of 9.0±4.2 months, 
it had better clinical outcomes in non-target vessel PCI-relat-
Table 3. One-year MACE in the COR and MVR groups
Variables COR group (n=701) MVR group (n=247) p
Total MACEs (%) 102 (14.6) 32 (13.0) 0.330
Death (%) 015 (2.1) 05 (2.0) 0.822
Cardiac 009 (1.3) 02 (0.8) 0.519
Noncardiac 006 (0.9) 03 (1.2) 0.682
MI (%) 004 (0.7) 02 (0.8) 0.910
STEMI 003 (0.4) 00 (0) 0.293
NSTEMI 001 (0.1) 02 (0.8) 0.116
Revascularization events (%) 082 (11.7) 25 (10.1) 0.301
TVR 021 (3.0) 13 (5.3) 0.190
Nontarget vessel PCI 058 (8.3) 12 (4.9) 0.053
CABG 003 (0.4) 00 (0) 0.194
MACEs: major adverse cardiac events, MI: myocardial infarction, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-seg-
ment elevation myocardial infarction, TVR: target vessel revascularization, PCI: percutaneous coronary intervention, CABG: coronary artery 
bypass graft, COR: culprit-vessel-only revascularization, MVR: multivessel revascularization
Fig. 2. One-year MACE-free survival in the COR and MVR groups. 
MACE: major adverse cardiac event, COR: culprit-vessel-only re-
vascularization, MVR: multivessel revascularization.
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ed events than with the treatment of IRA alone. However, the 
additional treatment of non-IRA during primary PCI or in-
dex hospitalization, resulted in a similar risk of death, MI, TVR, 
and CABG compared with the culprit-vessel-only procedure. 
Revascularization of the nonIRA probably prevented myo-
cardial ischemia, and these differences were associated with 
better clinical outcomes in the multivessel PCI group of the 
present study.
Due to the increased numbers of implanted coronary stents, 
multivessel PCI was prone to higher in-stent restenosis rates.
18) 
However in the present study, the TLR and TVR rates were 
statistically similar between the two groups. The reason for the 
higher in-hospital mortality rates in the culprit-vessel-only 
group despite the absence of differences in the baseline clini-
cal characteristics and complications is not clear. It might be 
associated with other factors, such as indications for PCI (elec-
tive, urgent, and emergent), presence of chronic total obstruc-
tion, and duration of procedure.
According to the current guidelines, PCI should be perform-
ed only in IRA, at least in patients without cardiogenic sh-
ock.
10)11) However, data from the National Cardiovascular 
Data Registry showed that multivessel PCI should not be 
performed in even hemodynamically unstable patients.
19) 
This is based on the hypothesis that single-vessel PCI has a 
more favorable benefit-to-risk ratio and better financial im-
plications. Some studies suggest that the more conservative 
strategy of treating only the IRA could avoid the complica-
tions arising from longer procedures, such as the larger use of 
Table 4. One-year MACE rate in the CR and IR subgroups
Variables CR subgroup (n=182) IR subgroup (n=779) p
Total MACE (%) 16 (9.5) 117 (15.0) 0.039
Death (%) 02 (1.2) 018 (2.3) 0.321
    Cardiac 02 (1.2) 009 (1.2) 0.995
    Noncardiac 00 (0) 009 (1.2) 0.157
MI (%) 01 (0.6) 005 (0.6) 0.798
    STEMI 00 (0) 003 (0.4) 0.414
    NSTEMI 01 (0.6) 002 (0.3) 0.485
Revascularization events (%) 13 (7.7) 094 (12.1) 0.068
    TVR 10 (6.0) 024 (3.1) 0.156
     Nontarget vessel PCI 03 (1.8) 067 (8.6) 0.002
    CABG 00 (0) 003 (0.4) 0.407
MACEs: major adverse cardiac events, MI: myocardial infarction, STEMI: ST-segment elevation myocardial infarction, NSTEMI: non-ST-seg-
ment elevation myocardial infarction, TVR: target vessel revascularization, PCI: percutaneous coronary intervention, CABG: coronary artery 
bypass graft, CR: complete revascularization, IR: Incomplete revascularization
Fig. 3. A: one-year MACE-free survival in the CR and IR subgroups. B: one-year nontarget vessel percutaneous coronary intervention-free sur-
vival in the CR and IR subgroups. MACE: major adverse cardiac event, CR: complete revascularization, IR: Incomplete revascularization.
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a contrast medium with a potentially increased risk of con-
trast-induced nephropathy (CIN), increased administration 
or radiation, as well as the danger of ischemia in noninfarct-
ed myocardial regions.
20)21)
In recent years, with the development of new advanced 
devices and the use of platelet glycoprotein IIb/IIIa inhibitors, 
the outcome of multivessel PCI has markedly improved.
22)23)
Some reports have indicated that the multivessel approach 
is safe and cost-effective. Brener et al.
24) retrospectively examin-
ed more than 100,000 patients with acute coronary syndro-
mes, and demonstrated a similar incidence of in-hospital ev-
ents between patients receiving single and multivessel treat-
ment. Ijsselmuiden et al.
8) randomly assigned 219 patients 
with acute coronary syndromes to culprit-only versus MVR, 
and they found that the multivessel approach had better 
outcomes by decreasing the need for further interventions. 
A recent randomized trial by Politi et al.
12) has shown that in 
214 patients with STEMI and multivessel CAD treated with 
primary PCI, COR angioplasty was associated with the high-
est rate of MACE compared with multivessel treatment, and 
that the patients scheduled for staged revascularization ex-
perienced a similar rate of MACE as the patients undergoing 
complete simultaneous treatment of non-IRA during the 
mean 2.5-year follow-up period. The findings in the present 
study were similar to those of the randomized trial by Politi 
et al. in which the incidence of repeat revascularization and 
in-hospital mortality were higher in the single-vessel strategy. 
As the definition of MACE and the follow-up duration in the 
present study were different from those in the trial discussed 
above, the total MACE results were different. Although the 
study by Kim et al.
25) using the same KAMIR data focused on 
NSTEMI patients, the findings in the present study were also 
similar to those of the said study, in which the incidence of in-
hospital mortality was higher in the culprit-only group, MVR 
reduced nonTVR, and there were no significant differences 
in the TLR.
Only one case of CIN was observed in the MVR group and 
in the IR subgroup. The rates of the other procedure-related or 
procedure-nonrelated complications were not different be-
tween the COR and MVR groups. Therefore, it was found 
that compared with the single-vessel approach, MVR is safe 
and is associated with a lower risk of nontarget PCI at a mean 
follow-up of 9.0±4.2 months. Moreover, CR is associated with 
a low risk of MACE. This result is attributable mainly to the 
lower incidence of nontarget vessel PCI in the CR subgroup 
compared with the COR group, and the result is mainly at-
tributable to the nine added events of nontarget vessel PCI in 
85 patients of the MVR group but of the IR subgroup. A pos-
sible explanation for the protective effect of multivessel PCI 
is that it allows a more complete treatment of other potentially 
unstable plaques. Indeed, the inflammatory reaction arising 
during acute coronary syndromes, and responsible for plaque 
instability is not limited to the culprit lesion, but involves the 
entire coronary tree.
4)
Although simultaneous revascularization was not distingu-
ished from staged revascularization, the results suggest that 
the multivessel and complete approach during primary PCI 
or index hospitalization is safe and is possibly less expensive 
than an incomplete approach, through a reduction in the 
probability of further unplanned procedures.
Limitations
The possible limitations of the present study were the im-
balance in the number of patients in the two groups and the 
difference in the LVEF. The lack of data on stent thrombosis 
and CIN during the follow-up period also limits the compari-
son of safety between MVR and culprit-only revasculariza-
tion. The present study was not a randomized controlled tri-
al, and a selection bias may have existed. However, due to the 
absence of significant differences in the baseline characteris-
tics in this study, propensity score matching was not needed 
in the present study.
Since protocol on selection did not exist, the selection of 
the culprit vessel under similar conditions varied among op-
erators. In patients with multivessel PCI, simultaneous PCI 
could not be distinguished from staged PCI during index 
hospitalization. The registry has no information on this dis-
tinction. Although, the analysis was conducted by adjusting 
all the possible confounding factors, other factors could be as-
sociated with the clinical outcomes.
Conclusions
In-hospital mortality was higher in the culprit-vessel-only 
PCI group than in the multivessel angioplasty group, and 
was also higher in the IR subgroup than in the CR subgroup.
Although multivessel angioplasty during primary PCI 
with DES for STEMI did not reduce the rates of death, rein-
farction, TLR, TVR, and CABG compared with culprit-ves-
sel-only PCI at one year, CR was associated with reduced non-
TVR events. This finding of the present study should be fur-
ther corroborated in a randomized controlled trial, and if con-
firmed, it may eventually lead to the recommendation of mul-
tivessel and CR for patients with STEMI and multivessel CAD.
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